期刊文献+

基于靶向纳米递药系统用于胰腺癌化疗中的研究现状

Research progress based on targeted nano-drug delivery system for pancreatic cancer chemotherapy
原文传递
导出
摘要 胰腺癌是一种恶性程度较高、诊断和治疗均较困难的消化道系统肿瘤。胰腺癌的传统化疗方案靶向性不高,治疗效率低,存在一系列的药物不良反应。近年来纳米靶向递药系统迅猛发展,为胰腺癌的治疗提供了许多的新思路。本文综述了近年来基于靶向纳米递药系统用于胰腺癌化疗的研究进展,从被动靶向、物理化学靶向、主动靶向和化疗药物的联合运载四个方面中的应用进行介绍,以期为胰腺癌的临床治疗提供新的思路和方法。 Pancreatic cancer is a highly malignant tumor of the digestive system that is difficult to diagnose and treat. Traditional chemotherapy regimens for pancreatic cancer are not highly targeted, with low treatment efficiency and a series of adverse reactions.In recent years, the rapid development of nano-targeted drug delivery systems has provided many new ideas for the treatment of pancreatic cancer. This article reviews the research progress in the treatment of pancreatic cancer based on targeted nano-drug delivery systems in recent years, from the four aspects of passive targeting, physicochemical targeting, active targeting and combined delivery of chemotherapeutic drugs. The clinical treatment of cancer provides new ideas and methods.
作者 接丽莉 塔伊尔·艾海提 李振华 JIE Li-li;TAYIER Ai-hai-ti;LI Zhen-hua(School of Pharmacy,China Medical University,Shenyang 110122,Liaoning Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2022年第9期1016-1019,共4页 The Chinese Journal of Clinical Pharmacology
基金 中国医科大学引进人才启动基金资助项目(1210619010) 2021中国医科大学“双一流”建设专项基金资助项目(3110210603)。
关键词 胰腺癌 纳米递药系统 肿瘤靶向 研究进展 pancreatic cancer nano drug delivery system tumor targeting research progress
  • 相关文献

参考文献3

二级参考文献19

  • 1BURRIS H A, MOORE M J, ANDERSEN J, et al. Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer: a randomized trial[ J]. J Clin Oncol, 1997,15 ( 6 ) : 2403 - 2413.
  • 2MOORE M J, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pan- creatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15) : 1960 -1966.
  • 3PARMAR M K, TORRI V, STEVART L, et al. Extracting summary statistics to perform Meta - analysis of the published literature for survival endpoint [ J ]. Stat Med, 1998,17 ( 24 ) : 2815 - 2834.
  • 4LIM J Y, CHO J H, LEE S J, et al. Gemcitabine combined with capecitabine compared to gemcitabine with or without Erlotinib as first -line chemotherapy in patients with advanced pancreatic cancer [J]. Cancer Res Treat, 2015, 47(2): 266-273.
  • 5WANG J P, WU C Y, YEH Y C, et al. Erlotinib is effective in pan- creatic cancer with epidermal growth factor receptor mutations : a ran- domized, open - label, prospective trial[ J ]. Oncotarget, 2015, 6 (20) : 18162 - 18173.
  • 6KHALIL M A, QIAO W, CARLSON P, et al. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer [ J ]. Invest New Drugs, 2013, 31(5) : 1375 -1383.
  • 7KIM M A, LEE H S, LEE H E, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[ J ]. Histopathology, 2008, 52 (6) : 738 - 746.
  • 8过雪丹,徐伟,孙春花,杭猛,陈暑波.厄洛替尼联合吉西他滨治疗晚期胰腺癌疗效观察[J].临床合理用药杂志,2012,5(5):21-22. 被引量:6
  • 9Raffaele Pezzilli,Dario Fabbri,Andrea Imbrogno.Pancreatic ductal adenocarcinoma screening:New perspectives[J].World Journal of Gastroenterology,2012,18(36):4973-4977. 被引量:8
  • 10乔明曦,张晓君,巴爽,胡海洋,赵秀丽,陈大为.肿瘤干细胞靶向给药系统的研究进展[J].药学学报,2013,48(4):477-483. 被引量:10

共引文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部